Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
Patient advocates Andrew Scott from the Global Liver Institute and Achim Kautz from Germany share their backgrounds, perspective, goals, and strategies with the Surfers.
Naim Alkhouri and Mazen Noureddin discuss the kinds of tools they developed in pursuit of a task Stephen Harrison defines as “making the wheel run smoother.”
The NAIL-NIT leaders explore exactly what makes it so challenging to develop FDA test criteria that match the overall picture of whether a drug is succeeding or not.
NAIL-NIT Retrospective Analysis co-chairs Naim Alkhouri and Jörn Schattenberg share their general plans and “passionate first projects” for this group.
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
This episode is Sponsored by Resoundant.
How can epidemiology-driven data modeling improve our setting strategies and targets for diagnostic and drug development?
